INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Icahn School of Medicine at Mount Sinai
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (85)
2024
-
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS
Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272
-
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
Cancer, Vol. 130, Núm. 6, pp. 886-900
-
Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
Dermatology and Therapy, Vol. 14, Núm. 3, pp. 593-612
-
SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer
Cell Reports, Vol. 43, Núm. 3
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
-
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Blood Advances, Vol. 8, Núm. 1, pp. 194-206
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis
CMAJ. Canadian Medical Association Journal, Vol. 66, Núm. 3, pp. E310-E320
-
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 5, pp. 385-393
-
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Leukemia and Lymphoma
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
Cancer, Vol. 129, Núm. 13, pp. 2035-2046
-
Examining the gut microbiota from several human-biting tick species in Northwestern Spain
Journal of medical entomology, Vol. 60, Núm. 5, pp. 1081-1087
-
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy
Gut, Vol. 73, Núm. 3, pp. 496-508
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
-
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840
-
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222
2022
-
Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease
Cancers, Vol. 14, Núm. 1
-
Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, Núm. 3, pp. 461-475
-
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Blood, Vol. 140, Núm. 21, pp. 2248-2260